No profile data available.
Protagenic Therapeutics, Inc. (PTIX) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 2 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$5.53 million. In Q2 2025 (the quarter ended June 30, 2025) revenue was $0. Its market capitalization was $1.39 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York.
Protagenic Therapeutics reported $0 in revenue for fiscal year 2024. In Q2 2025 revenue was $0.
$1.39 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Psyence Biomedical Ltd. (PBM), Silo Pharma, Inc. (SILO), Oragenics, Inc. (OGEN), PaxMedica, Inc. (PXMD).